Lanxiang Wu

机构：The Affiliated Yongchuan Hospital of Chongqing Medical University, PharmacoGenetics (China), Chongqing Medical University · ORCID：0000-0002-6687-2552

发表论文 54 篇 · 总被引 1322 次 · h-index 22

代表论文

• Significance of Single-Nucleotide Variants in Long Intergenic Non-protein Coding RNAs (2020 · Frontiers in Cell and Developmental Biology · 被引 55)
• CircSETD3 mediates acquired resistance to gefitinib in non-small lung cancer cells by FXR1/ECT2 pathway (2022 · The International Journal of Biochemistry & Cell Biology · 被引 50)
• CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer (2024 · Cancer Genetics · 被引 48)
• Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer (2022 · Molecular Omics · 被引 42)
• circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway (2020 · Molecular Therapy — Nucleic Acids · 被引 41)
• Ct-OATP1B3 promotes high-grade serous ovarian cancer metastasis by regulation of fatty acid beta-oxidation and oxidative phosphorylation (2022 · Cell Death and Disease · 被引 32)